Start Free Trial

Developing an infection-blocking pan-coronavirus vaccine

Covid · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Active
Status

Opportunity Overview

Viruses run a highly competitive race to outpace our immune system and establish infection. Our immune responses can't usually expand fast enough to win the race so are unable to prevent viruses spreading amongst our cells and being transmitted on to others. Therefore, it is essential to train our immune systems with more effective vaccines to allow them to shutdown viruses before they gain a foothold, both within an individual and at a population level. In the last 20 years, there have been 3 global pandemics caused by coronaviruses passing from animals to humans: SARS, MERS and COVID-19. Even the accelerated development of vaccines against SARS-CoV-2 was not fast enough to prevent worldwide spread of the virus, with devastating morbidity and mortality. Existing vaccines have become less effective at preventing infection because they target the spike protein that rapidly mutated to escape immunity; making new vaccines against the latest variant means we will always be a step behind the virus. As a crucial component of proactive pandemic preparedness, we are therefore developing a pan-coronavirus vaccine with the capacity to provide broad protection against new animal coronaviruses spreading into humans, as well as against current and future, potentially more lethal, SARS-CoV-2 variants. Our vaccine, 'PanCoVax', will generate immunity that targets regions that are essential for virus replication. We found these regions to be highly conserved across all variants and also all versions of coronaviruses in the animal kingdom. Our vaccine will therefore be 'future variant proof' and offer protection against pandemics from new coronaviruses transmitted from animals. Another limitation of existing SARS-CoV-2 vaccines is that they do not induce immunity able to shut down the virus before it multiplies and can be transmitted on to others. However, PanCoVax mimics a type of immune response we observed in a subset of individuals who were able to 'abort' SARS-CoV-2 so rapidly...

This is one of 69 active United Kingdom Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyCovid
CountryUnited Kingdom
CategoryPharmaceuticals
Response dueNot specified / rolling
StatusActive - open for responses
Official sourceView original notice

Related Opportunities in United Kingdom

BLC0111 - Mobile Preliminary Roadside Drug Testing
GLP In-Vivo Preclinical Safety and Pharmacokinetic Study of a Novel Dual-Drug Coated Balloon Formulation
GLIOMATCH: The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics
A Broadly Protective, Thermostable and Rapidly Deployable Pre-Pandemic pan-H5Nx Influenza Vaccine with mucosal delivery potential
Accelerating Combination Drug Discovery for Obesity with AI
GenomeMET: Metrology for genomic profiling to support early cancer detection and precision medicine
Control of Taenia solium in a hyper-endemic region of Uganda: Assessing optimal mass drug administration strategies in the human and porcine hosts
Precision Medicine for the Treatment of VEXAS Syndrome

See every United Kingdom Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →